No Data
No Data
Shareholders May Not Be So Generous With TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation And Here's Why
Key Insights TOT BIOPHARM International will host its Annual General Meeting on 26th of June Total pay for CEO Jun Liu includes CN¥3.73m salary The total compensation is similar to the average for
Dongyao Pharmaceutical-B (01875.HK) proposes to adopt the 2024 Restricted Share Award Scheme
Gelonghui, May 29丨Dongyao Pharmaceutical-B (01875.HK) issued an announcement. The board of directors recommended the adoption of the 2024 restricted share award plan, which is valid for ten (10) years from the date of adoption. This will enable the company to attract and retain necessary talents, motivate group employees, and enable the company to flexibly grant share-based rewards on existing shares in addition to new shares.
TOT BIOPHARM International Company Limited (HKG:1875) Soars 28% But It's A Story Of Risk Vs Reward
TOT BIOPHARM International Company Limited (HKG:1875) shareholders would be excited to see that the share price has had a great month, posting a 28% gain and recovering from prior weakness. Not all
Dongyao Pharmaceutical-B: CDMO achieved remarkable results in strategic transformation and officially turned losses into profits
Dongyao Pharmaceutical-B (1875.HK) performance progress has reached a new milestone. On May 10, the company announced its results for the first quarter of 2024. Operating revenue increased 68% year over year to about 223 million yuan, and net profit was about 7.409 million yuan. The company fully turned a loss into a profit. According to the announcement, the increase in revenue was mainly due to continued growth in the CDMO/CMO business and a sharp increase in sales of self-developed products. Looking back at the company's past performance, it can be seen that Dongyao Pharmaceutical-B's performance has grown rapidly in just a few years after fully transforming and expanding its CDMO business in 2021. This transformation not only enabled the company's
Dongyao Pharmaceutical-B (01875) achieved net profit of about 7.409 million yuan in the first quarter, turning a year-on-year loss into profit
Dongyao Pharmaceutical-B (01875) announced its results for the first quarter of 2024. Operating revenue increased 68% year on year to about 223 million yuan, and net profit was about 7.409 million yuan, turning a year-on-year loss into a profit.
TOT BIOPHARM-B: ANNUAL REPORT 2023
No Data